Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Medicover AB (publ)
  6. News
  7. MarketScreener Strategies
    MCOV B   SE0009778848

MEDICOVER AB (PUBL)

(MCOV B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medicover AB (publ) : The underlying trend is to the upside

08/27/2021 | 03:16am EDT
long trade
Target price hit
Entry price : 246.5SEK | Target : 274SEK | Stop-loss : 224SEK | Potential : 11.16%
The underlying tendency is to the upside for shares in Medicover AB (publ) and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Investors have an opportunity to buy the stock and target the SEK 274.
Medicover AB (publ) : Medicover AB (publ) : The underlying trend is to the upside
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses
  • With an expected P/E ratio at 395.33 and 467.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 1 311 M 1 520 M 1 520 M
Net income 2021 95,4 M 111 M 111 M
Net Debt 2021 310 M 360 M 360 M
P/E ratio 2021 412x
Yield 2021 0,05%
Capitalization 39 680 M 4 604 M 46 008 M
EV / Sales 2021 30,5x
EV / Sales 2022 28,7x
Nbr of Employees 32 000
Free-Float 40,1%
Upcoming event on MEDICOVER AB (PUBL)
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 267,50 €
Average target price 26,51 €
Spread / Average Target -90,1%
EPS Revisions
Managers and Directors
Fredrik Rňgmark Chief Executive Officer & Director
Joe Ryan Chief Financial Officer
Fredrik Stenmo Chairman
Andrew Vallance-Owen Chief Medical Officer
Jaroslaw Urbanczyk Chief Information Officer
Sector and Competitors